Daily Tomato Intake Linked to Greater Liver Fat Reduction in MASLD Trial

Metabolic dysfunction-associated steatotic liver disease now affects an estimated 1.3 billion people globally, a 143 percent rise since 1990, and ranks as the fastest-growing cause of liver cancer. Fat accumulates in the liver alongside at least one cardiometabolic risk factor such as elevated blood pressure or excess weight. A randomized controlled trial published in Nutrients tested whether a simple daily addition of tomatoes could change that trajectory. Seventy-nine adults followed either a tomato-supplemented diet or a tomato-free control diet for six weeks. The tomato group showed a greater reduction in hepatic steatosis, and the improvement occurred without major shifts in body weight, total fat, or abdominal fat.

Participants in the intervention arm ate 200 grams of raw tomatoes plus 50 grams of tomato sauce each day, all from the same producer. Controls avoided tomatoes. Researchers excluded heavy drinkers, anyone with a BMI above 30, and people older than 65. Most participants were men. Body composition, liver fat, liver stiffness, and cholesterol were tracked.

Hepatic steatosis declined in both groups, but the drop was larger among those eating tomatoes. Baseline liver fat levels were comparable. No significant between-group differences appeared for liver stiffness, blood lipids, liver enzymes, or BMI. The authors concluded that tomato consumption may reduce hepatic fat accumulation independently of substantial changes in weight or adiposity. Circulating lycopene and other carotenoids were not measured, leaving the precise active components unidentified.

Outside clinicians urged caution. Endocrinologist Randa Abdelmasih noted the modest effect size, short duration, and highly selected population. Most patients seen in practice carry BMI values above 30, type 2 diabetes, or more advanced disease, limiting direct generalizability. Internist Jonathan Jennings pointed out that the trial treated a single cardiometabolic risk factor as sufficient for enrollment even though multiple factors compound risk, and that type 2 diabetes carries greater weight for MASLD progression than hypertension alone.

The authors themselves described the work as exploratory and hypothesis-generating. No improvements were recorded in fibrosis scores, insulin resistance markers, inflammatory markers, or overall body composition. Sustained weight loss of roughly 10 percent or more remains the intervention with the strongest evidence for reversing steatohepatitis and fibrosis. Tomatoes and tomato products can also aggravate reflux or add calories in some formulations, so individual tolerance matters.

The tomato finding sits inside a larger pattern. A meta-analysis of 28 studies covering more than 624,000 participants linked higher scores on established diet-quality measures to significantly lower risk of chronic liver disease. Whole-food approaches that emphasize nutrient density appear repeatedly in nutritional guidance as foundational rather than optional. The trial did not claim tomatoes alone reverse disease progression. It showed that a low-cost, widely available food produced a measurable reduction in liver fat over a short period in a defined group of adults.

MASLD tracks the same rise in metabolic syndrome, obesity, and sedentary living that has driven other chronic conditions. When a common vegetable produces an independent effect on hepatic steatosis, the data point toward food composition as a lever that does not require new pharmaceuticals or extreme caloric restriction. Larger and longer trials will be needed to test durability, identify active compounds, and examine results in patients with higher BMIs and more complex risk profiles. Until then, the evidence supports including tomatoes within broader whole-food patterns already associated with lower chronic liver disease risk.